Health
2.0
Poland debates access to costly therapies vs. public budget constraints
Published 1 d ago1 sourceEvidence: Reported
RzeczpospolitaLow-rated sourcePL
HealthReportedLow
2.0
Serbia registers 38 biosimilars; Europe total 161
Serbia has 38 registered biosimilars, compared to 161 in Europe, indicating a narrower market access. The gap suggests potential delays in regulatory approvals or market entry, which may affect patient access and healthcare costs. The data is from ALIMS, the Serbian medicines agency.
Score Breakdown
Mosaic Score2.0
Model confidence0.5
Significance0.1
Source credibility0.2
Related signals
8 foundHumanitarian
9.1
Gaza volunteer doctors detail hospital collapse amid ongoing Israeli offensive
Published 1 d ago6 sourcesEvidence: Reported
SeverityHighAssessedDeveloping storyAl JazeeraIL · PS
Health
7.2
Idaho Abortion Ban Spurs OB-GYN Exodus, Endangering Maternal Care
Published 10 h ago1 sourceEvidence: Reported
SeverityHighAssessedDeveloping storyNew York TimesLow-rated sourceUS
Humanitarian
7.1
Sudan's civil war drives medicine costs beyond reach for chronically ill
Published 2 d ago1 sourceEvidence: Reported
SeverityHighAssessedDeveloping storyAl JazeeraSD
Cyber
6.7
Oracle Health breach exposes medical records of nearly 20 million patients
Published 2 d ago1 sourceEvidence: Reported
SeverityHighAssessedDeveloping storyFox NewsLow-rated sourceUS
Politics
6.3
Polish Health Act Amendments Risk Chaos; KO Deputies Silent
Published 2 d ago5 sourcesEvidence: Unknown
SeverityModerateAssessedDeveloping storyGazeta WyborczaPL
Health
6.2
Roche reviews Germany investments over healthcare cost cuts; Gilead bowel drug advances
Published 1 d ago4 sourcesEvidence: Reported
SeverityModerateAssessedDeveloping storySTAT NewsLow-rated sourceDE · US
Markets
6.1
Greek regulator clears CrediaBank-Europe Holdings merger; completion by end-October
Published 1 d ago3 sourcesEvidence: Reported
SeverityModerateCapital.grLow-rated sourceGR